Dare Bioscience, Inc. (27)

Browse by Contract Category

Contracts

Form of Nonstatutory Stock Option Agreement for grants under the Dar Bioscience, Inc. 2022 Stock Incentive Plan (Filed With SEC on June 24, 2022)
Consent, Waiver and Stand-By License Agreement, dated March 30, 2022, by and among TriLogic Pharma, LLC, and MilanaPharm LLC, Dare Bioscience, Inc., and Organon International GmbH (Filed With SEC on May 12, 2022)
Warrant Agreement to purchase shares of common stock of the registrant with Aquilo Partners, L.P., entered into as of October 16, 2016 (Filed With SEC on March 31, 2022)
Cooperative Research and Development Agreement entered into as of July 8, 2021 between Dare Bioscience, Inc. and the Eunice Kennedy Schriver National Institutes of Child Health... (Filed With SEC on November 10, 2021)
Grant Agreement between Dar Bioscience, Inc. and the Bill & Melinda Gates Foundation effective as of June 30, 2021 (Filed With SEC on August 12, 2021)
Agreement and Plan of Merger, dated November 10, 2019, Dar Bioscience, Inc., MC Merger Sub, Inc., Microchips Biotech, Inc., and Shareholder Representative Services LLC, as the... (Filed With SEC on November 12, 2019)
Form of Incentive Stock Option Agreement for grants under the Dar Bioscience, Inc. 2022 Stock Incentive Plan (Filed With SEC on June 24, 2022)
Dar Bioscience, Inc. 2022 Stock Incentive Plan (Filed With SEC on June 24, 2022)
Amended & Restated Non-Employee Director Compensation Policy (as amended through January 2022) (Filed With SEC on May 12, 2022)
Exclusive license agreement by and between Organon International GmbH and Dar Bioscience, Inc., dated as of March 31, 2022 (Filed With SEC on May 12, 2022)
Amendment to License Agreement effective as of September 21, 2021 by and among Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on November 10, 2021)
Sales Agreement, dated as of (Filed With SEC on October 13, 2021)
Sales Agreement, dated as of April (Filed With SEC on April 8, 2021)
Dar Bioscience, Inc. Change in Control Policy (effective October 15, 2019) (Filed With SEC on January 5, 2021)
Dar Bioscience, Inc. Employment Offer Letter to John Fair, dated April 24, 2018 (Filed With SEC on January 5, 2021)
Amendment No. 1 to Employment Agreement between Dar Bioscience, Inc. and Lisa Walters-Hoffert dated as of March 9, 2020 (Filed With SEC on May 14, 2020)
Amendment No. 1 to Employment Agreement between Dar Bioscience, Inc. and Sabrina Martucci Johnson dated as of March 9, 2020 (Filed With SEC on May 14, 2020)
Registration Rights Agreement, dated April 22, 2020, by and between Dar Bioscience, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on April 23, 2020)
Purchase Agreement, dated April 22, 2020, by and between Dar Bioscience, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on April 23, 2020)
Amendment No. 2 to the License Agreement entered into as of December 3, 2019 between Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on March 27, 2020)
Amendment No. 1 to Assignment Agreement entered into as of December 4, 2019 between Dar Bioscience, Inc. and Hammock Pharmaceuticals, Inc (Filed With SEC on March 27, 2020)
License Agreement dated as of January 10, 2020 between Bayer HealthCare LLC and Dar Bioscience, Inc (Filed With SEC on March 27, 2020)
Description of securities of the registrant (Filed With SEC on March 27, 2020)
Dar Bioscience, Inc. Performance Bonus Plan (Filed With SEC on November 12, 2019)
Underwriting Agreement dated as of April 9, 2019, by and between Dar Bioscience, Inc. and Roth Capital Partners, LLC, as the representative for the underwriters named therein (Filed With SEC on April 9, 2019)
First Amendment to the License Agreement effective as of December 5, 2018 by and among Dar Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC (Filed With SEC on April 1, 2019)
Assignment Agreement by and between Dar Bioscience, Inc. and Hammock Pharmaceuticals, Inc. effective as of December 5, 2018 (Filed With SEC on April 1, 2019)